BPC-157 Quick Start
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a sequence identified in human gastric juice. It is studied primarily in animal models of tendon, ligament, gut, and vascular injury. This page treats both the injectable and nasal-spray formats as research-context references.
This guide is an educational research reference. It does not diagnose, treat, or prescribe, and is not medical advice. Speak with a licensed clinician before considering any compound.
BPC-157 Dosing Protocols
The injectable (subcutaneous) and nasal-spray formats are documented as two separate protocols. The numbers are research-planning ranges drawn from published preclinical protocols and community-derived references — not personal dosing recommendations. The short plasma half-life reported in animal PK studies (He et al., 2022) is why split-dose schedules appear in the literature.
Injection — Subcutaneous
| Band | Per dose | Frequency |
|---|---|---|
| Low | 250 mcg | Once daily |
| Standard | 250 mcg | Twice daily |
| High | 500 mcg | Twice daily |
Nasal Spray
| Band | Per dose | # of sprays | Frequency |
|---|---|---|---|
| Low | 300 mcg | 3 sprays | Once daily |
| Standard | 300 mcg | 3 sprays | Twice daily |
| High | 500 mcg | 5 sprays | Twice daily |
Cycle guidelines
| Approach | Duration | Review point | Best for |
|---|---|---|---|
| Standard | 4–6 weeks | Week 4 | General research planning |
| Extended | 6–8 weeks | Week 6 | Stubborn-injury research models |
| Long | 8–12 weeks | Week 8 | Slow-remodeling tissue research |
Off periods of 2–4 weeks between cycles are common in research planning. There is no published human cycling RCT, so these durations are conventions rather than validated regimens.
BPC-157 Reconstitution Guide
BPC-157 ships as a freeze-dried (lyophilized) powder. The amount of bacteriostatic (BAC) water added sets the concentration and draw volume for the injectable vial. Nasal sprays ship pre-mixed and ready to use.
Injection — 2 mL
| BAC | Conc. | 250 mcg |
|---|---|---|
| 2 mL | 5,000 mcg/mL | 0.05 mL · 5 u |
| 3 mL | 3,333 mcg/mL | 0.075 mL · 7.5 u |
Units are U-100 insulin-syringe units (100 u = 1.0 mL).
Reconstitution steps
- Inspect the vial. Confirm the label, expected milligram amount, and that the powder looks dry and intact.
- Wipe the stoppers. Use an alcohol swab on both the BAC water and peptide vial stoppers.
- Draw BAC water. 2 mL into the injectable vial.
- Inject down the wall. Release the water slowly down the inside wall, not directly onto the powder.
- Swirl, do not shake. Roll gently until clear. Shaking can damage the peptide.
- Verify clarity. Solution should be clear and colorless. Discard if cloudy or particulate.
- Refrigerate. Store at 2–8 °C. Do not freeze the reconstituted solution.
How to use the nasal spray
- Prime first use. Pump 2–3 sprays into a tissue until a fine, even mist appears.
- Position. Tilt the head slightly forward; insert the tip just inside one nostril, aimed slightly outward toward the ear — not at the septum.
- Spray and breathe. Press once while breathing in gently; do not sniff hard, which sends the solution down the throat instead of onto the mucosa.
- Alternate nostrils. For multi-spray doses, switch nostrils each spray to spread absorption and limit irritation.
- Count per the protocol. Use the sprays-per-dose shown above; if a dose isn't a whole number, round up.
- Between uses. Wipe the tip, recap, and refrigerate.
How BPC-157 Works
In plain terms, animal studies suggest BPC-157 helps damaged tissue grow new blood supply and signals cells to migrate into injured areas — which is why it recurs as a research tool in tendon, gut, and vessel-injury models.
Reported mechanisms include upregulation of VEGFR2 and activation of the Akt–eNOS pathway, raising nitric oxide production in vessel walls (Hsieh et al., 2017; 2020). Others include FAK–paxillin complexes that support cell migration and attachment, plus JAK-2 and ERK1/2 activity. These are preclinical findings, not human clinical proofs.
Angiogenesis
Promotes new blood-vessel formation in animal models — the central mechanism most reviews focus on.
Cell migration
Reported to support fibroblast and endothelial migration into injured tissue.
Inflammation balance
Animal data report downregulation of NF-κB and Nos2 in injury settings.
Open question
Whether these mechanisms are clinically meaningful in humans is not yet established.
Who Should Avoid BPC-157
Because human safety data is limited, any eligibility decision should involve a licensed clinician. Categories where caution is most consistently flagged:
Active or prior cancer
Angiogenesis supports tumor growth too — a theoretical concern unresolved in humans (Sehgal et al., 2025).
Pregnancy & lactation
No published human reproductive or lactation safety data exists.
Tested athletes
On the WADA Prohibited List under S0 since 2022. Use is an anti-doping rule violation.
Vascular-active medications
BPC-157 affects nitric oxide signaling; review with a clinician if on related meds.
BPC-157 Side Effects & Safety
Reported effects fall into three buckets: observed effects in pilot work, theoretical mechanism risk, and route-specific issues.
Observed in pilots
A 2025 IV pilot in two adults (10 mg, 20 mg) reported no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers (Lee et al., 2025).
Theoretical risk
The angiogenesis pathway that aids repair also supports tumor growth — flagged especially for current/prior cancer.
Injection-site reactions
Mild redness or small bumps are the most common short-term issue in community use; rotate sites.
Quality-control risk
Grey-market material carries contamination and mis-dosing risk separate from the molecule itself — verify against a COA.
Timeline & What to Monitor
| Timeframe | Commonly tracked | Notes |
|---|---|---|
| Days 1–7 | Acute reports, injection-site response | Anti-doping violation begins immediately for tested athletes. |
| Weeks 1–2 | Range-of-motion / functional self-report | Reflects symptom-level change, not structural healing. |
| Weeks 4–6 | Tendon/ligament endpoints (animal models) | Rodent tendon papers commonly assess at this window. |
| Weeks 6–12 | Extended-cycle community reports | No human RCT covers this duration. |
These reference points come from preclinical literature and small pilots; they are not predictions of personal outcomes.
Clinical Evidence Context
Direct human evidence is limited to a small number of pilot studies; animal evidence is much larger and underpins almost all mechanism work.
Human pilots (~30 patients)
A 12-patient knee-pain case series (2021), a 12-woman interstitial cystitis pilot (2024), and a 2-adult IV safety pilot (2025).
Systematic review
Vasireddi et al. (2025) concluded human evidence remains insufficient to support clinical recommendations.
Mechanism literature
VEGFR2 activation, eNOS/NO signaling, and tendon-cell behavior in cultured cells and rodent models.
Open question
No published Phase 2 or Phase 3 human RCT exists. Planning ranges are not clinically validated doses.
Storage & Handling
| State | Storage | Notes |
|---|---|---|
| Lyophilized (powder) | −20 °C long-term; fridge short-term | Powder is more stable than reconstituted solution. |
| Reconstituted (liquid) | 2–8 °C | Use within ~3–4 weeks; do not freeze. |
| Appearance | Clear, colorless | Discard cloudy or particulate solutions. |
Mistakes & Troubleshooting
- Cloudy vial after reconstitution. Do not use it — discard and replace.
- Wrong BAC volume. Recalculate concentration before drawing; injection assumes 2 mL, spray assumes 10 mL.
- Missed dose. Skip and continue at the next scheduled time; do not double-dose.
- Persistent injection-site reaction. Rotate sites; use a fresh syringe and swab each session.
- Left out overnight. Treat reconstituted solution as compromised and discard.
- Confused about format. Vials and sprays are not interchangeable milligram-for-milligram — check the label.
BPC-157 vs TB-500
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Class | 15-aa pentadecapeptide | Thymosin β-4 fragment (17 aa) |
| Research focus | Tendon, gut, vessel models | Cell migration; soft-tissue / muscle |
| Half-life | Short (<30 min, animal PK) | Longer signaling-relevant action |
| Pairing | Often combined as the "Wolverine" pairing; available pre-blended in GLOW. | |
Blood Tests & Monitoring
BPC-157 lacks established human lab-monitoring standards, so markers are pathway-based and general rather than peptide-specific.
| Marker | Why | Timing |
|---|---|---|
| CBC w/ differential | Flags infection, anemia, immune changes | Baseline |
| CMP | Liver, kidney, electrolytes, glucose | Baseline |
| CRP / ESR | Broader inflammation context | Optional |
Frequently Asked Questions
What is BPC-157?
A synthetic 15-amino-acid peptide whose sequence was identified from a protein in human gastric juice. It is studied mainly in animal models of tendon, gut, and vessel injury.
How is the injection dosed vs the nasal spray?
They are separate protocols. Injection commonly references ~250 mcg once or twice daily. The spray delivers 100 mcg per 0.1 mL spray (10 mg in 10 mL), so the equivalent low band is 3 sprays (300 mcg) per dose. See the dosing section for both tables.
How is BPC-157 reconstituted?
For injection, a 10 mg vial with 2 mL BAC water yields 5,000 mcg/mL, so 250 mcg = 0.05 mL = 5 units. The spray ships pre-mixed and delivers 100 mcg per spray. Always confirm against the label.
Why is it banned by WADA?
It has been on the WADA Prohibited List under S0 (non-approved substances) since 2022 and remains on the 2025 list.
Is this page medical advice?
No. It is an educational research reference and does not diagnose, treat, or prescribe. Consult a licensed clinician before considering any compound.
References
- Chang CH, et al. Promoting effect of BPC-157 on tendon healing. J Appl Physiol (2011).
- Hsieh MJ, et al. Pro-angiogenic BPC-157 and VEGFR2 activation. J Mol Med (2017).
- Hsieh MJ, et al. BPC-157 and the Src–Cav-1–eNOS pathway. Sci Rep (2020).
- He L, et al. Pharmacokinetics and distribution of BPC-157 in rats and dogs. Front Pharmacol (2022).
- Sikiric P, et al. Stable gastric pentadecapeptide BPC-157. Curr Pharm Des (2011).
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J (2025).
- Lee E, et al. Safety of IV BPC-157 in humans: a pilot study. Altern Ther Health Med (2025).
- Sehgal P, et al. BPC-157: cytoprotection and tissue repair. Pharmaceuticals (2025).
- World Anti-Doping Agency. Prohibited List 2025.